References
- Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182:4499 - 506; http://dx.doi.org/10.4049/jimmunol.0802740; PMID: 19342621
- Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253 - 68; http://dx.doi.org/10.1038/nri3175; PMID: 22437938
- Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 2012; 144:250 - 68; http://dx.doi.org/10.1016/j.clim.2012.06.003; PMID: 22858650
- Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70:4335 - 45; http://dx.doi.org/10.1158/0008-5472.CAN-09-3767; PMID: 20484028
- Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25:2546 - 53; http://dx.doi.org/10.1200/JCO.2006.08.5829; PMID: 17577033
- Mao Y, Poschke I, Wennerberg E, Pico de Coaña Y, Brage SE, Schultz I, et al. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res 2013; 73:3877 - 87; http://dx.doi.org/10.1158/0008-5472.CAN-12-4115; PMID: 23633486
- Poschke I, Mougiakakos D, Kiessling R. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother 2011; 60:1161 - 71; http://dx.doi.org/10.1007/s00262-011-1012-8; PMID: 21626032
- Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011; 118:5498 - 505; http://dx.doi.org/10.1182/blood-2011-07-365825; PMID: 21972293
- Johansson CC, Egyházi S, Masucci G, Harlin H, Mougiakakos D, Poschke I, et al. Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunol Immunother 2009; 58:1085 - 94; http://dx.doi.org/10.1007/s00262-008-0631-1; PMID: 19039588
- Poschke I, Mao Y, Adamson L, Salazar-Onfray F, Masucci G, Kiessling R. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother 2012; 61:827 - 38; http://dx.doi.org/10.1007/s00262-011-1143-y; PMID: 22080405